Citius Pharmaceuticals, Inc. (CTXR)
NASDAQ: CTXR · Real-Time Price · USD
0.7011
+0.0280 (4.16%)
At close: May 22, 2026, 4:00 PM EDT
0.6905
-0.0106 (-1.51%)
After-hours: May 22, 2026, 7:59 PM EDT
Citius Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Citius Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $5.00. The average 1-year stock price forecast is 613.17% higher than the current stock price, while the lowest is $4.00 (+470.53%) and the highest is $6.00 (+755.80%).
Price Target: $5.00 (+613.17%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Citius Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $4 | Strong Buy | Initiates | $4 | +470.53% | May 18, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +755.80% | Mar 11, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +755.80% | Dec 4, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +755.80% | Aug 13, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $6 | Strong Buy | Maintains | $6 | +755.80% | Jun 30, 2025 |
Financial Forecast
Revenue This Year
79.86M
Revenue Next Year
146.63M
from 79.86M
Increased by 83.62%
EPS This Year
1.69
from -3.38
EPS Next Year
2.85
from 1.69
Increased by 68.07%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 82.2M | 150.9M | ||||||
| Avg | 79.9M | 146.6M | ||||||
| Low | 76.7M | 140.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 89.0% | ||||||
| Avg | - | 83.6% | ||||||
| Low | - | 76.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.74 | 2.93 | ||||||
| Avg | 1.69 | 2.85 | ||||||
| Low | 1.63 | 2.73 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 73.0% | ||||||
| Avg | - | 68.1% | ||||||
| Low | - | 61.5% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.